We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

28 hedge funds and large institutions have $4.23M invested in CASI Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more capital invested

Capital invested by funds: $2.41M → $4.23M (+$1.82M)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

4% more funds holding

Funds holding: 27 → 28 (+1)

0.02% more ownership

Funds ownership: 0.38% → 0.4% (+0.02%)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

Holders
28
Holders Change
+1
Holders Change %
+3.7%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$83K
2
VF
Virtu Financial
New York
+$47.6K
3
HCM
Howland Capital Management
Massachusetts
+$28.2K
4
GC
Guggenheim Capital
Illinois
+$14.3K
5
Renaissance Technologies
Renaissance Technologies
New York
+$7.82K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$22K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$19K
3
WSC
Wellington Shields & Co
New York
-$18.1K
4
UBS Group
UBS Group
Switzerland
-$6.06K
5
BlackRock
BlackRock
New York
-$3.64K

CASI Hedge Fund Activity: Q3 2017 in Review

28 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2017, worth a combined $4.23M — up 75% from $2.41M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CASI positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $83K. The largest seller was Citadel Advisors, exiting entirely with an estimated $22K sold.

  • 28 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2017, up from 27 in Q2 2017.
  • Funds reported $4.23M of CASI Pharmaceuticals stock for Q3 2017, up 75% quarter-over-quarter.
  • 4 funds opened new CASI Pharmaceuticals positions in Q3 2017 and 3 closed out, a net change of +1 holder.
  • The largest CASI Pharmaceuticals buyer in Q3 2017 was Vanguard Group, an estimated $83K added.
  • The largest CASI Pharmaceuticals seller in Q3 2017 was Citadel Advisors, an estimated $22K sold.

Based on aggregated 13F filings for Q3 2017.